Search

Displaying results 901 - 910 of 5878 in total
  1. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2640] To know more about the individual components of the ergoloid mixture, please visit [DB11275], [DB11274], [DB11273] and [DB13345]. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives

    Synonyms: co-dergocrine mesilate, co-dergocrine mesylateCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    to thrombin [A35558]. … The procoagulation potential of andexanet alfa is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, andexanet alfa is unable to bind to membrane surfaces and

  3. Drug

    AT-GTX-502

    go.drugbank.com/drugs/DB17001
    Experimental

    AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.

  4. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).

  5. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease

  6. Drug

    Epinephrine

    go.drugbank.com/drugs/DB00668
    ApprovedInvestigationalVet approved

    On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths [L4353]. … to drugs, animal serums and other allergens, and to prolong the action of infiltration anesthetics [F2136].

    Mixtures: Xylocaine 2% W Epinephrine 1:100000, Xylocaine 2% W Epinephrine 1:200000Products: Gingi Pak Cord No 1, Gingi-pak Max Z-twist No 1
  7. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.

    Products: VARDENAFIL TEVA GENERICS
  8. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

  9. Drug

    Heme iron polypeptide

    go.drugbank.com/drugs/DB11067
    Approved

    Mixtures: VP-HEME One, VP-HEME One
  10. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve